Business Context and Reporting Period
This Form 8-K Current Report from Skye Bioscience, Inc. (SKYE) is dated June 18, 2026. The filing addresses regulatory compliance issues regarding the listing of the Company's common stock on The Nasdaq Stock Market.
Key Financial Metrics
Based on the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, stockholders' equity was reported as $9,011,804. The filing does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes and Listing Status
- Equity Deficiency: The Company was notified of non-compliance with Nasdaq Global Market Listing Rule 5450(b)(1)(A) due to stockholders' equity falling below the $10,000,000 minimum requirement.
- Market Transfer: On June 18, 2026, the Company received approval to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective June 23, 2026. The Capital Market requires a lower minimum stockholders' equity of $3,000,000.
- Bid Price Deficiency: The Company remains non-compliant with the Minimum Bid Price Requirement (Rule 5450(a)(1)), as the stock closed below $1.00 per share for 30 consecutive business days prior to March 17, 2026.
- Compliance Timeline: The Company has an Initial Compliance Period until September 14, 2026, to regain compliance with the $1.00 minimum bid price requirement.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the closing bid price and consider available options to resolve the bid price deficiency. The filing explicitly states there can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement by the September 14, 2026 deadline or maintain compliance with other Nasdaq Listing Rules. Failure to comply could result in delisting.
Investor Verification Checklist
- Verify the effective date of the transfer to the Nasdaq Capital Market (June 23, 2026).
- Monitor the daily closing bid price of SKYE stock to assess progress toward the $1.00 minimum requirement.
- Review the Form 10-Q for the quarter ended March 31, 2026, for detailed financial statements regarding the $9,011,804 stockholders' equity figure.
- Watch for future announcements regarding specific actions taken to address the bid price deficiency before the September 14, 2026 deadline.